Literature DB >> 21192233

Effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first to second-line antiretroviral regimens in resource-limited settings.

Andrew N Phillips1, Deenan Pillay, Geoff Garnett, Diane Bennett, Marco Vitoria, Valentina Cambiano, Jens Lundgren.   

Abstract

BACKGROUND: There is concern that antiretroviral therapy (ART) use with only clinical monitoring for failure will result in high rates of transmission of virus with resistance to drugs currently in use.
METHODS: A stochastic simulation model of transmission of HIV, natural history and the effect of ART, was developed and used to predict the proportion of new infections with resistance according to whether and when viral load monitoring is introduced.
RESULTS: In our base model, there was predicted to be 12.4% of new HIV infections with primary antiretroviral resistance in 2020 if clinical monitoring is used throughout, compared with 5.4 and 6.1% if viral load-guided switching (based on viral load measured every 6 months, with switch determined by a value >500 copies/ml) was introduced in 2010 or 2015, respectively. The death rate for those on ART was lowest when viral load monitoring was used, but the overall death rate in all infected people was higher if viral load monitoring was introduced at the expense of scale-up in HIV diagnosis and ART initiation beyond their 2010 coverage levels (4.7 compared with 3.1 per 100 person-years).
INTERPRETATION: To preserve current first-line drugs for the long term there is an eventual need for some form of cheap and practical viral load monitoring in resource-limited settings. However, a delay in introduction of 5 years has limited consequences for resistance transmission so the current priority for countries' ART programmes is to increase HIV testing and provide treatment for all those in need of ART.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21192233     DOI: 10.1097/QAD.0b013e328344037a

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  46 in total

1.  Prediction of treatment failure using 2010 World Health Organization Guidelines is associated with high misclassification rates and drug resistance among HIV-infected Cambodian children.

Authors:  Benjamin P Westley; Allison K DeLong; Chhraing S Tray; Dim Sophearin; Elizabeth M Dufort; Eric Nerrienet; Leeann Schreier; Joseph I Harwell; Rami Kantor
Journal:  Clin Infect Dis       Date:  2012-04-26       Impact factor: 9.079

2.  gems: An R Package for Simulating from Disease Progression Models.

Authors:  Nello Blaser; Luisa Salazar Vizcaya; Janne Estill; Cindy Zahnd; Bindu Kalesan; Matthias Egger; Thomas Gsponer; Olivia Keiser
Journal:  J Stat Softw       Date:  2015-03       Impact factor: 6.440

3.  Outcomes following virological failure and predictors of switching to second-line antiretroviral therapy in a South African treatment program.

Authors:  Victoria Johnston; Katherine L Fielding; Salome Charalambous; Gavin Churchyard; Andrew Phillips; Alison D Grant
Journal:  J Acquir Immune Defic Syndr       Date:  2012-11-01       Impact factor: 3.731

4.  Emerging antiretroviral drug resistance in sub-Saharan Africa: novel affordable technologies are needed to provide resistance testing for individual and public health benefits.

Authors:  Gert U van Zyl; Lisa M Frenkel; Michael H Chung; Wolfgang Preiser; John W Mellors; Jean B Nachega
Journal:  AIDS       Date:  2014-11-28       Impact factor: 4.177

5.  Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring.

Authors:  Viktor von Wyl; Valentina Cambiano; Michael R Jordan; Silvia Bertagnolio; Alec Miners; Deenan Pillay; Jens Lundgren; Andrew N Phillips
Journal:  PLoS One       Date:  2012-08-08       Impact factor: 3.240

6.  Sustainable HIV treatment in Africa through viral-load-informed differentiated care.

Authors:  Andrew Phillips; Amir Shroufi; Lara Vojnov; Jennifer Cohn; Teri Roberts; Tom Ellman; Kimberly Bonner; Christine Rousseau; Geoff Garnett; Valentina Cambiano; Fumiyo Nakagawa; Deborah Ford; Loveleen Bansi-Matharu; Alec Miners; Jens D Lundgren; Jeffrey W Eaton; Rosalind Parkes-Ratanshi; Zachary Katz; David Maman; Nathan Ford; Marco Vitoria; Meg Doherty; David Dowdy; Brooke Nichols; Maurine Murtagh; Meghan Wareham; Kara M Palamountain; Christine Chakanyuka Musanhu; Wendy Stevens; David Katzenstein; Andrea Ciaranello; Ruanne Barnabas; R Scott Braithwaite; Eran Bendavid; Kusum J Nathoo; David van de Vijver; David P Wilson; Charles Holmes; Anna Bershteyn; Simon Walker; Elliot Raizes; Ilesh Jani; Lisa J Nelson; Rosanna Peeling; Fern Terris-Prestholt; Joseph Murungu; Tsitsi Mutasa-Apollo; Timothy B Hallett; Paul Revill
Journal:  Nature       Date:  2015-12-03       Impact factor: 49.962

7.  Delayed switch of antiretroviral therapy after virologic failure associated with elevated mortality among HIV-infected adults in Africa.

Authors:  Maya L Petersen; Linh Tran; Elvin H Geng; Steven J Reynolds; Andrew Kambugu; Robin Wood; David R Bangsberg; Constantin T Yiannoutsos; Steven G Deeks; Jeffrey N Martin
Journal:  AIDS       Date:  2014-09-10       Impact factor: 4.177

8.  Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naive populations beginning treatment: modelling study and economic analysis.

Authors:  Andrew N Phillips; Valentina Cambiano; Alec Miners; Paul Revill; Deenan Pillay; Jens D Lundgren; Diane Bennett; Elliott Raizes; Fumiyo Nakagawa; Andrea De Luca; Marco Vitoria; Jhoney Barcarolo; Joseph Perriens; Michael R Jordan; Silvia Bertagnolio
Journal:  Lancet HIV       Date:  2014-10-14       Impact factor: 12.767

9.  Cost effectiveness analysis of clinically driven versus routine laboratory monitoring of antiretroviral therapy in Uganda and Zimbabwe.

Authors:  Antonieta Medina Lara; Jesse Kigozi; Jovita Amurwon; Lazarus Muchabaiwa; Barbara Nyanzi Wakaholi; Ruben E Mujica Mota; A Sarah Walker; Ronnie Kasirye; Francis Ssali; Andrew Reid; Heiner Grosskurth; Abdel G Babiker; Cissy Kityo; Elly Katabira; Paula Munderi; Peter Mugyenyi; James Hakim; Janet Darbyshire; Diana M Gibb; Charles F Gilks
Journal:  PLoS One       Date:  2012-04-24       Impact factor: 3.240

10.  Cost-effectiveness of different strategies to monitor adults on antiretroviral treatment: a combined analysis of three mathematical models.

Authors:  Daniel Keebler; Paul Revill; Scott Braithwaite; Andrew Phillips; Nello Blaser; Annick Borquez; Valentina Cambiano; Andrea Ciaranello; Janne Estill; Richard Gray; Andrew Hill; Olivia Keiser; Jason Kessler; Nicolas A Menzies; Kimberly A Nucifora; Luisa Salazar Vizcaya; Simon Walker; Alex Welte; Philippa Easterbrook; Meg Doherty; Gottfried Hirnschall; Timothy B Hallett
Journal:  Lancet Glob Health       Date:  2013-12-10       Impact factor: 26.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.